Jeff Jones
Stock Analyst at Oppenheimer
(0.83)
# 3,845
Out of 4,898 analysts
94
Total ratings
22.35%
Success rate
-17.65%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Outperform | $56 → $53 | $44.90 | +18.04% | 5 | Jun 27, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $21.87 | +101.19% | 3 | Jun 24, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Outperform | $20 → $15 | $4.36 | +244.04% | 3 | May 29, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $11 → $10 | $1.17 | +754.70% | 8 | May 16, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $3.60 | +594.44% | 2 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $1.30 | +1,212.74% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $4.35 | +290.80% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $35.28 | +143.76% | 2 | May 8, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $60 → $56 | $8.36 | +569.86% | 9 | May 7, 2025 | |
| EVH Evolent Health | Maintains: Outperform | $28 → $18 | $11.36 | +58.45% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.98 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $4.00 | +300.00% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 → $9 | $2.81 | +220.28% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.45 | +3,003.45% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $14.85 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.08 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,920 | $3.31 | +57,906.04% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.75 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.34 | +1,019.40% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $0.63 | +11,802.87% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $2.67 | +41,098.50% | 2 | Nov 17, 2022 |
Kymera Therapeutics
Jun 27, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $44.90
Upside: +18.04%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $21.87
Upside: +101.19%
Y-mAbs Therapeutics
May 29, 2025
Maintains: Outperform
Price Target: $20 → $15
Current: $4.36
Upside: +244.04%
Chemomab Therapeutics
May 16, 2025
Maintains: Outperform
Price Target: $11 → $10
Current: $1.17
Upside: +754.70%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $3.60
Upside: +594.44%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $1.30
Upside: +1,212.74%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $4.35
Upside: +290.80%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $35.28
Upside: +143.76%
Corbus Pharmaceuticals Holdings
May 7, 2025
Maintains: Outperform
Price Target: $60 → $56
Current: $8.36
Upside: +569.86%
Evolent Health
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $11.36
Upside: +58.45%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $4.98
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $4.00
Upside: +300.00%
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $2.81
Upside: +220.28%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.45
Upside: +3,003.45%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $14.85
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.08
Upside: -
May 25, 2023
Maintains: Outperform
Price Target: $1,920
Current: $3.31
Upside: +57,906.04%
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $3.75
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.34
Upside: +1,019.40%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $0.63
Upside: +11,802.87%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $2.67
Upside: +41,098.50%